
zzso adult patients were zzso to receive zzso on days 1 and 8 and zzso on days 4 and 11 or vice versa, given zzso over a zzso period before zzso 10 received 2 zzso zzso zzso zzso 11 received 8 zzso zzso zzso zzso Active and total zzso growth hormone zzso and zzso growth factor 1 levels were monitored at baseline zzso days before day 1), during treatment days, and at end of study zzso zzso zzso adverse events zzso by zzso criteria and cardiac zzso did not differ between zzso and zzso No grade 3/4 toxicity or stimulation of zzso growth was zzso The peak increase of zzso a biological marker of zzso action, was 25 zzso zzso with zzso and 42 zzso zzso with zzso zzso Morning zzso total zzso levels were higher zzso for zzso patients at end of study zzso zzso zzso than at baseline zzso zzso zzso zzso growth factor 1 levels did not zzso At day 8, zzso of patients preferred zzso to zzso as against zzso at the end of zzso zzso intake and zzso symptoms, measured to explore preliminary zzso did not differ between zzso and zzso zzso is well tolerated and safe in patients with advanced zzso For safety, zzso and patients' preference for treatment, no difference was observed between the zzso and zzso zzso 

